Organisation paid for research Program year 2025 Source: CMS Open Payments

Texas Oncology - Austin Midtown

Neither a doctor nor a teaching hospital

Research payments

$3,477,758

616 payments

Through program year 2025, Texas Oncology - Austin Midtown is reported as receiving $3,477,758 in research payments, across 616 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $81,226 10
2024 Research $29,889 1
2023 Research $1,631,162 95
2022 Research $373,996 119
2021 Research $970,555 263
2020 Research $385,262 117
2019 Research $5,668 11

Breakdown

Who paid Research payments · program years 2019–2025
  1. Amgen Inc. $1,778,577 17 payments
  2. Seattle Genetics, Inc. $1,617,955 589 payments
  3. AbbVie, Inc. $81,226 10 payments
Studies the money was for Research payments · program years 2019–2025
  1. AMG 510 Ph1b Master Protocol 20190135 $1,545,850 6 payments
  2. A Phase 1 Study of SEA-BCMA in Patients With Relapsed or Refractory Multiple Myeloma $1,097,984 274 payments
  3. A Single Cohort Phase 2 Trial Investigating the Impact of G-CSF Primary Prophylaxis for Advanced Stage Hodgkin Lymphoma Patients Treated With A+AVD $425,460 222 payments
  4. SELECT-1st relapse after len-containing regimen $185,901 3 payments
  5. A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL) $74,371 9 payments
  6. A Dual-cohort, Open-label, Phase 2 Study of Brentuximab Vedotin and CHP (A+CHP) in the Frontline Treatment of Subjects With Peripheral T-cell Lymphoma (PTCL) With Less Than 10% CD30 Expression $54,400 55 payments
  7. AMG 510 - Adv. KRAS G12C solid tumors_20190135 $26,789 3 payments
  8. A Phase 1 Study of SGN-TGT in Subjects With Advanced Malignancies $14,448 9 payments
  9. A Randomized, Double-blind, Placebo-Controlled, Active-Comparator, Multicenter, Phase 3 Study of Brentuximab Vedotin or Placebo in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL) $12,430 7 payments
  10. 1st replapse after len-containing regimen $8,000 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record